Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours

Executive Summary

It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.

Advertisement

Related Content

Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
Efficiency Bows To Scrutiny: '90s Drug Development Timelines Have Doubled
Case Studies: How Three Public Companies Financed R&D In A Tough Market
Public Biopharma Financings Plunge In 2016, But Is It A Sign Of Health?
VC Roundup: More Funds Raise Cash For Biotech; Morphic Closes $51.5m Series A
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
IPO Update: With No New Offerings, Kadmon Steals The Spotlight
IPO Update: Haircuts Needed To Price Biotech Offerings
VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back
IPO Update: Three More Biotechs Squeeze Through The Window

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel